Fenretinide a New Drug for Dry Macular Degeneration
Dry macular degeneration
Dry macular degeneration is the slow deterioration or break down of the retinal cells in the central part of the retina. The macula is responsible for the central vision used for reading, driving, and fine vision. Dry macular degeneration has no treatment at this time. Vitamin supplements are the only recommended method for trying to slow the progression of dry macular degeneration. Nearly thirty percent of people over the age of seventy five have macular degeneration.
Fenretinide is a new drug being studied for help with dry macular degeneration. Sirion Therapeutics has received fast-track status from the Food and Drug Administration for Fenretinide. Fast-track means that the Food and Drug Administration believes the drug has significant potential and the Food and Drug Administration will facilitate the investigation. This could mean that the drug will be available in the not too distant future. Sirion received this determination from the encouraging Phase II results in its clinical study.
The study compared Fenretinide (oral medication) with a placebo (sugar pill) in dry macular degeneration. In the current study, Fenretinide appears to result in a fifty percent reduction in the progression of dry macular degeneration. The drug does not improve or cure dry macular degeneration but it may help people maintain their vision for a much longer period of time. This could be the first Food and Drug Administration approved medicine for use in slowing the progression of dry macular degeneration.